Levobeta C Retard (Carbidopa, Levodopa)

The combination works by pairing levodopa, which crosses the blood‑brain barrier and is converted into dopamine, with carbidopa, which blocks peripheral conversion of levodopa. This increases the amount of levodopa that reaches the central nervous system, restoring dopamine activity that is deficient in Parkinsonian disorders.

Dosing is individualized and determined by the prescribing physician based on disease severity, patient response, and tolerability. The prescriber will select the appropriate strength and frequency of the extended‑release tablets to achieve optimal symptom control while minimizing side effects.

Safety data for Carbidopa/Levodopa during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levobeta C Retard provides a controlled, extended‑release delivery of levodopa, resulting in more stable plasma concentrations and potentially fewer peaks and troughs compared with immediate‑release tablets. This can lead to smoother symptom control and may reduce the frequency of motor fluctuations for many patients.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Levobeta C Retard is taken orally as an extended‑release tablet. Swallow the tablet whole with a glass of water; do not crush, chew, or split it, as this would disrupt the controlled‑release mechanism. It may be taken with or without food, according to the prescriber's guidance.

Serious adverse events include dyskinesia (involuntary movements), hallucinations or other psychotic symptoms, and severe orthostatic hypotension that can lead to fainting. Patients should report any sudden changes in movement, mood, or blood pressure to their healthcare provider promptly.

Individuals with known hypersensitivity to carbidopa, levodopa, or any excipients should avoid the product. It is also contraindicated in patients currently taking non‑selective MAO inhibitors, and caution is advised for those on dopamine‑blocking antipsychotics or with severe cardiovascular disease.